Table 1 Indications Included in Identified Studies by Intervention
Drug | Indication(s) |
|---|---|
CTLA-4 inhibitors | |
 Ipilimumab | Melanoma (n = 25), NSCLC (n = 3), mCRC (n = 1), SCLC (n = 1), RCC (n = 1), pancreatic (n = 1) |
 Tremelimumab | Melanoma (n = 3) |
PD-1 inhibitors | |
 Nivolumab | NSCLC (n = 14), melanoma (n = 14), RCC (n = 3), urothelial (n = 2), SCCHN (n = 1), GC (n = 1), mCRC (n = 1), Hodgkin’s disease (n = 1), SCLC (n = 1) |
 Pembrolizumab | Melanoma (n = 9), NSCLC (n = 6), urothelial (n = 2), mCRC (n = 2), GC (n = 1), breast cancer (n = 1), SCCHN (n = 1) |
PD-L1 inhibitors | |
 Atezolizumab | NSCLC (n = 6), melanoma (n = 2), urothelial (n = 3), RCC (n = 2) |
 Avelumab | NSCLC (n = 1), Merkel cell cancer (n = 1), urothelial (n = 1) |
 Durvalumab | NSCLC (n = 2), urothelial (n = 1) |